TC Medical(600763)2024-10-28 10:02Revenue and Profit - Revenue for the third quarter was RMB 822.55 million, a slight increase of 0.04% year-over-year[2] - Net profit attributable to shareholders decreased by 9.10% to RMB 188.46 million in the third quarter[2] - Operating revenue for the first three quarters of 2024 reached 2.23 billion yuan, compared to 2.18 billion yuan in the same period last year[14] - Net profit for the first three quarters of 2024 was 601.76 million yuan, slightly down from 612.02 million yuan in the same period last year[16] - Net profit attributable to shareholders of the parent company was RMB 498.27 million, compared to RMB 511.73 million in the previous period[18] Assets and Liabilities - Total assets increased by 7.21% to RMB 6.22 billion compared to the end of the previous year[3] - Shareholders' equity rose by 8.07% to RMB 4.13 billion compared to the end of the previous year[3] - Total assets increased to 6.22 billion yuan, up from 6.01 billion yuan in the previous period[12] - Total liabilities decreased to 1.73 billion yuan, down from 1.88 billion yuan in the previous period[13] - Total equity attributable to the parent company increased to 4.13 billion yuan, up from 3.81 billion yuan in the previous period[13] - The company's total equity increased to 4.5 billion yuan, up from 4.12 billion yuan in the previous period[13] Cash Flow - Operating cash flow for the first nine months increased by 3.37% to RMB 646.77 million[2] - Net cash flow from operating activities was RMB 646.77 million, compared to RMB 625.70 million in the previous period[19] - Net cash flow from investing activities was negative RMB 258.55 million, compared to negative RMB 638.49 million in the previous period[20] - Net cash flow from financing activities was negative RMB 385.08 million, compared to positive RMB 63.74 million in the previous period[20] - Cash and cash equivalents at the end of the period were RMB 597.22 million, compared to RMB 680.50 million in the previous period[20] Earnings and Shareholder Information - Basic earnings per share (EPS) for the third quarter decreased by 8.70% to RMB 0.42[2] - Total number of ordinary shareholders at the end of the reporting period is 85,980[7] - Hangzhou Baoqun Industrial Group Co., Ltd. holds 151,589,199 shares, representing 33.89% of the total shares[7] - ICBC-Credit Suisse Healthcare Mix Fund holds 15,945,510 shares, representing 3.56% of the total shares[7] - Minority shareholders' profit and loss was RMB 103.49 million, compared to RMB 100.29 million in the previous period[18] - Total comprehensive income attributable to shareholders of the parent company was RMB 594.09 million, compared to RMB 608.92 million in the previous period[18] Financial Expenses and Investments - Financial expenses increased by 51.39% due to higher lease liability interest and reduced interest income[6] - Long-term equity investments as of September 30, 2024, amount to 918,604,908.12 RMB, compared to 767,267,812.39 RMB at the end of 2023[11] - Fixed assets as of September 30, 2024, amount to 815,758,051.19 RMB, compared to 840,426,205.34 RMB at the end of 2023[11] - Construction in progress as of September 30, 2024, amount to 1,061,059,999.47 RMB, compared to 839,183,666.99 RMB at the end of 2023[11] - Short-term borrowings remained stable at 80 million yuan[12] - Long-term borrowings decreased to 179 million yuan, down from 189 million yuan in the previous period[12] Operating Costs and R&D - Operating costs for the first three quarters of 2024 were 1.61 billion yuan, up from 1.54 billion yuan in the same period last year[14] - R&D expenses for the first three quarters of 2024 were 41.05 million yuan, down from 43.85 million yuan in the same period last year[16] Other Financial Metrics - The company's goodwill increased by 45.31% due to the acquisition of Loudi Dental Hospital[6] - Prepayments increased by 131.64% due to higher advance rental income[6] - Contract liabilities decreased by 44.55% due to a reduction in advance customer payments[6] - Monetary funds as of September 30, 2024, amount to 597,943,865.14 RMB, compared to 594,462,752.21 RMB at the end of 2023[11] - Accounts receivable as of September 30, 2024, amount to 151,639,601.28 RMB, compared to 137,507,334.72 RMB at the end of 2023[11] - Total current assets as of September 30, 2024, amount to 890,284,819.76 RMB, compared to 969,063,956.25 RMB at the end of 2023[11] - Cash received from sales of goods and services was RMB 2.22 billion, compared to RMB 2.16 billion in the previous period[19]